EUCTR2006-003258-98-FR进行中（未招募）不适用
A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III study to assess the long term efficacy, carry-over effect and safety of two dosing regimens of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis
Stallergenes S.A.0 个研究点目标入组 780 人开始时间: 2006年10月11日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 780
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female outpatients aged 18 to 50 years (inclusive).
- •Grass pollen-related allergic rhinoconjunctivitis for at least the last two pollen seasons.
- •Sensitised to grass pollen (positive skin prick test and IgE level of at least Class 2).
- •Total symptom score on the Retrospective Rhinoconjunctivitis Total Symptom Score (RRTSS) during the previous pollen season of greater than or equal to 12 out of a possible score of 18.
- •Female patients of childbearing potential must be willing and able to sign written informed consent stating that they will use appropriate contraception and not plan a pregnancy for the first 3 years of this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with symptoms of rhinoconjunctivitis during the grass pollen season due to sensitisation to allergens other than grass pollen may not be included. Patients must be asymptomatic to all other allergens during the grass pollen season. Patients who have allergic rhinitis due to perennial allergen may not be included.
- •Asthma requiring treatment other than beta-2 inhaled agonists.
- •Patients who have received desensitisation treatment for grass pollen.
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy - A Phase II dose-finding study of atacicept in RARheumatoid arthritisEUCTR2006-004140-23-DEMerck Serono Int, a branch of Laboratoires Seron SA an affiliate of Merck KGaA, Darmstadt, Germany240
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multi-national Phase II/III study of the safety and efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adult patients suffering from house dust mite allergic rhinitisEUCTR2007-001454-77-CZStallergenes S.A486
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, multi-centre, multi-national Phase II / III follow-up study to assess long-term efficacy and safety of three different dose regimens of Oralgen® Grass Pollen in patients with grass pollen related allergic rhinoconjunctivitis (follow-up study to AB0602). - NAMedDRA version: 9.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisAllergic rhinoconjunctivitisEUCTR2007-002477-31-SKArtu Biologicals Europe B.V.560
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of one dose of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to children suffering from grass pollen rhinoconjunctivitisEUCTR2005-002502-34-DKStallergenes S.A.300
进行中（未招募）
1 期
Atacicept Phase II/III in Generalized Systemic Lupus Erythematosus (APRIL SLE)MedDRA version: 14.1 Level: PT Classification code 10042945 Term: Systemic lupus erythematosus System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2007-003698-13-GBMerck Serono S.A. Geneva. An affiliate of Merck KGaA, Darmstadt, Germany